Recombinant Mouse Klk1 protein (rFc Tag)
种属
Mouse
纯度
>90 %, SDS-PAGE
标签
rFc Tag
生物活性
未测试
验证数据展示
产品信息
| 纯度 | >90 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 |
Not tested |
| 来源 | HEK293-derived Mouse Klk1 protein Pro19-Asp261 (Accession# P15947) with a rabbit IgG Fc tag at the C-terminus. |
| 基因ID | 16612 |
| 蛋白编号 | P15947 |
| 预测分子量 | 52.5 kDa |
| SDS-PAGE | 52-65 kDa, reducing (R) conditions |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
Klk1, or kallikrein 1, is a serine protease and an important member of the kallikrein family. It is synthesized and secreted in various tissues, including the kidneys and salivary glands. The core function of Klk1 is to catalyze the cleavage of kininogen, generating highly bioactive kinins such as bradykinin. Kinins are key inflammatory mediators and vasoactive peptides that regulate blood pressure, inflammatory responses, pain perception, and vascular permeability through their receptors. Therefore, Klk1 and its kinin system play a central role in pathological processes such as hypertension, heart failure, inflammatory diseases, and angioedema. This system is also a critical downstream pathway through which classic drugs like ACE inhibitors exert their effects, while Klk1 itself serves as a potential target for novel anti-inflammatory and analgesic drugs.
参考文献:
1. Zhou, Lisha et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 12,42 (2025): e07063. 2. Han, Siliang et al. American journal of translational research vol. 17,3 (2025) 1872-1881. 3. Adamopoulos, Panagiotis G et al. Genomics vol. 111,4 (2019): 642-652.
